Health-related quality-of-life findings for the prostate cancer prevention trial

Journal of the National Cancer Institute

Volumn 104, Issue 18, 2012, Pages 1373-1385

  Moinpour, Carol M ^a,g   Darke, Amy K ^b   Donaldson, Gary W ^c   Cespedes, Duane ^d   Johnson, Christine R ^e   Ganz, Patricia A ^f   Patrick, Donald L ^a,g   Ware, John E ^h   Shumaker, Sally A ⁱ   Meyskens, Frank L ^j   Thompson, Ian M ^k  

^a Cancer Prevention Program   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Shore Comprehensive Urology   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HYPERTENSION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SCALE; PHYSICAL FUNCTIONING SCALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; VITALITY SCALE;

5-ALPHA REDUCTASE INHIBITORS; ACTIVITIES OF DAILY LIVING; AGED; ANTICARCINOGENIC AGENTS; FINASTERIDE; HEALTH STATUS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84866677422     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs359     Document Type: Article

References (34)

1. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY, Investigators obotC. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community-based study. Clin Ther. 1995;17(5):956-969.
2. Girman CJ, Kolman C, Liss CL, et al. Effects of finasteride on healthrelated quality of life in men with symptomatic benign prostatic hyperplasia. Prostate. 1996;29(2):83-90.
3. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associates with benign prostatic hyperplasia. Urology. 1999;54(4):670-678.
4. Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665-669.
5. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7.
6. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-alphareductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994;3(2):177-182.
7. Gormley GJ, Brawley O, Thompson IM. The potential application of finasteride for chemoprevention of prostate cancer. Ann N Y Acad Sci. 1995;768:163-169.
8. Thompson IM, Coltman CA. Screening for prostate cancer: opportunities for prevention. Semin Urol Oncol. 1996;14(2):4-11.
9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;340(3):215-224.
10. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025-1035.
11. Moinpour CM, Lovato LC, Thompson IM, Jr, et al. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol. 2000;18(9):1942-1953.
12. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
13. McHorney C, Ware JE, Jr, Raczek A. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247-263.
14. Ware JE, Jr, Snow KK, Kosinski MA, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: Nimrod Press; 1993.
15. McHorney CA, Ware JE, Jr, Lu RJF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-46.
16. Stewart AL, Hays RD, Wells KB, Rogers WH. Development of measures of physical activity/exercise and tests of variations in physical activity levels within chronic disease groups in the medical outcomes study. Report no P-7781. Santa Monica, CA: RAND Corporation; 1993.
17. Stewart AL, Hays RD, Wells KB, Rogers WH, Spritzer KL, Greenfield S. Long-term functioning and well-being outcomes associated with physical activity and exercise in patients with chronic conditions in the medical outcomes study. J Clin Epidemiol. 1994;47(7):719-730.
18. Satia-Abouta J, Patterson RE, Schiller RN, Kristal AR. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med. 2002;34(5):493-501.
19. Block G, Clifford C, Maughton MD, Henderson M, McAdams M. A brief dietary screen for high fat intake. J Nutr Educ. 1989;21(5):199-207.
20. Barry MJ, Fowler F, Jr, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557.
21. Barry MJ, Fowler FJ, Jr, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33(4):AS145-AS155.
22. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc; 1996.
23. Laird NM, Ware JW. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
24. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16(11):3662-3673.
25. Donaldson G. Patient-reported outcomes and the mandate of measurement. Qual Life Res. 2008;17(10):1303-1313.
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers; 1988.
27. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008;1(3):174-181.
28. Rowland JH, Varricchio CG, Trimble EL, Gore-Langton RE. Clinical trials referral resource. Oncology. 2001;15(11):1455-1457.
29. Robert G, Descazeaud A, de la Taille A. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the highrisk patients and what are the best treatment options? Curr Opin Urol. 2011;21(1):42-48.
30. Parsons J, Schenk JM, Arnold K, et al. Finasteride reduces the risk of incident symptomatic benign prostatic hyperplasia. Paper presented at Late Breaking Science Forum, annual meeting of the American Urological Association; May 14-19, 2011; Washington, DC.
31. Parsons JK, Schenk JM, Arnold KB, et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. European Urology. In press.
32. Parsons JK, Mougey J, Lambert L, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104(1):63-68.
33. Engström G, Henningsohn L, Walker-Engström M-L, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by the Short Form 36 questionnaire. Scand J Urol Nephrol. 2006;40(6):485-494.
34. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103 (s3):4-11.